Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and c...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-01-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/456002 |
id |
doaj-8bcc771a750f4e519a19da3094eccd6e |
---|---|
record_format |
Article |
spelling |
doaj-8bcc771a750f4e519a19da3094eccd6e2020-11-24T23:02:07ZengKarger PublishersCase Reports in Oncology1662-65752017-01-0110112712910.1159/000456002456002Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell LymphomaAliénor GalinierVincent DelwailMathieu PuyadeAutoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this form of anaemia was not controlled with the usual chemotherapy. Ibrutinib was used when MCL with AIHA relapsed, and it allowed rapid remission of AIHA and rapid discontinuation of steroid therapy.http://www.karger.com/Article/FullText/456002Mantle cell lymphomaAutoimmune hemolytic anaemiaIbrutinib |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aliénor Galinier Vincent Delwail Mathieu Puyade |
spellingShingle |
Aliénor Galinier Vincent Delwail Mathieu Puyade Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma Case Reports in Oncology Mantle cell lymphoma Autoimmune hemolytic anaemia Ibrutinib |
author_facet |
Aliénor Galinier Vincent Delwail Mathieu Puyade |
author_sort |
Aliénor Galinier |
title |
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma |
title_short |
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma |
title_full |
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma |
title_fullStr |
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma |
title_full_unstemmed |
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma |
title_sort |
ibrutinib is effective in the treatment of autoimmune haemolytic anaemia in mantle cell lymphoma |
publisher |
Karger Publishers |
series |
Case Reports in Oncology |
issn |
1662-6575 |
publishDate |
2017-01-01 |
description |
Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this form of anaemia was not controlled with the usual chemotherapy. Ibrutinib was used when MCL with AIHA relapsed, and it allowed rapid remission of AIHA and rapid discontinuation of steroid therapy. |
topic |
Mantle cell lymphoma Autoimmune hemolytic anaemia Ibrutinib |
url |
http://www.karger.com/Article/FullText/456002 |
work_keys_str_mv |
AT alienorgalinier ibrutinibiseffectiveinthetreatmentofautoimmunehaemolyticanaemiainmantlecelllymphoma AT vincentdelwail ibrutinibiseffectiveinthetreatmentofautoimmunehaemolyticanaemiainmantlecelllymphoma AT mathieupuyade ibrutinibiseffectiveinthetreatmentofautoimmunehaemolyticanaemiainmantlecelllymphoma |
_version_ |
1725637410407055360 |